首页|FDA approved fluorine-containing drugs in 2023

FDA approved fluorine-containing drugs in 2023

扫码查看
This review profiles twelve fluorine-containing drugs approved by the US Food and Drug Administration(FDA)for the clinic in 2023.These small molecule drugs represent such therapeutic areas as cancer,neu-romuscular disorder,immunodeficiency,virology,and infectious diseases.Medicinal chemistry discovery,biological activity,and synthetic routes have been discussed for each drug.Also,new trends in structural positioning,functionality,and degree of fluorination are discussed.Besides fluorination,the importance of amino acid residues and chirality in the design of new pharmaceuticals is highlighted.

Fluorine-containing compoundsBlockbuster drugsPharmaceuticalsAnti-cancerDrug design and developmentAsymmetric synthesis

Qian Wang、Yeping Bian、Gagan Dhawan、Wei Zhang、Alexander E.Sorochinsky、Ata Makarem、Vadim A.Soloshonok、Jianlin Han

展开 >

Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources,College of Chemical Engineering,Nanjing Forestry University,Nanjing 210037,China

Jiangsu Province Geriatric Hospital,Nanjing 210024,China

School of Allied Medical Sciences,Delhi Skill and Entrepreneurship University,and Department of Biomedical Science,Acharya Narendra Dev College,University of Delhi,New Delhi 110019,India

Department of Chemistry,University of Massachusetts Boston,Boston,MA 02125,United States

V.P.Kukhar Institute of Bioorganic Chemistry and Petrochemistry,The National Academy of Sciences of Ukraine,Kyiv 02094,Ukraine

Department of Chemistry,University of Hamburg,Martin-Luther-King-Platz 6,Hamburg 20146,Germany

Department of Organic Chemistry Ⅰ,Faculty of Chemistry,University of the Basque Country UPV/EHU,Paseo Manuel Lardizábal 3,San Sebastián 20018,Spain

IKERBASQUE,Basque Foundation for Science,María Díaz de Haro 3,Plaza Bizkaia,Bilbao 48013,Spain

展开 >

2024

中国化学快报(英文版)
中国化学会

中国化学快报(英文版)

CSTPCD
影响因子:0.771
ISSN:1001-8417
年,卷(期):2024.35(11)